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Mitochondria are critically important in providing cellular energy ATP as well as their involvement in
anti-oxidant defense, fat oxidation, intermediary metabolism and cell death processes. It is well-estab-
lished that mitochondrial functions are suppressed when living cells or organisms are exposed to po-
tentially toxic agents including alcohol, high fat diets, smoking and certain drugs or in many patho-
physiological states through increased levels of oxidative/nitrative stress. Under elevated nitroxidative
stress, cellular macromolecules proteins, DNA, and lipids can undergo different oxidative modiﬁcations,
leading to disruption of their normal, sometimes critical, physiological functions. Recent reports also
indicated that many mitochondrial proteins are modiﬁed via various post-translation modiﬁcations
(PTMs) and primarily inactivated. Because of the recently-emerging information, in this review, we
speciﬁcally focus on the mechanisms and roles of ﬁve major PTMs (namely oxidation, nitration, phos-
phorylation, acetylation, and adduct formation with lipid-peroxides, reactive metabolites, or advanced
glycation end products) in experimental models of alcoholic and nonalcoholic fatty liver disease as well
as acute hepatic injury caused by toxic compounds. We also highlight the role of the ethanol-inducible
cytochrome P450-2E1 (CYP2E1) in some of these PTM changes. Finally, we discuss translational research
opportunities with natural and/or synthetic anti-oxidants, which can prevent or delay the onset of mi-
tochondrial dysfunction, fat accumulation and tissue injury.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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All living organisms require exogenous foods/nutrients for
producing energy in the form of ATP, which is needed for nu-
merous cellular functions. Most of the cellular energy is efﬁciently
produced in specialized organelles mitochondria by oxidative
phosphorylation. In addition to energy production, mitochondria
play an important role in other cellular functions such as fatty acid
oxidation, anti-oxidant defense, intermediary metabolism includ-
ing ammonia and glutamate detoxiﬁcation, synthesis of heme and
steroids, cell death process, and autophagy [1]. Recent reports
showed that mitochondria also undergo constant morphological
changes with fusion and ﬁssion, following the exposure to toxic
agents and/or under pathological conditions [2,3]. After decreased
glucose supply like during fasting or inefﬁcient oxidative phos-
phorylation in certain disease states, the mitochondrial fat oxida-
tion pathway becomes important in providing an alternative
source of energy (e.g., ketone bodies) [1]. Without these energy
supply mechanisms due to suppressed mitochondrial function
(i.e., mitochondrial dysfunction), living cells would die or become
susceptible to cell death processes (necrosis and apoptosis). In fact,
it is well-established that mitochondrial function in different tis-
sues is signiﬁcantly suppressed in numerous medical disorders
such as metabolic syndrome including obesity/diabetes, cardio-
vascular disorders, ischemia reperfusion injury (I/R)1 and cancer as
well as many neurological disorders like Alzheimer's disease and
Parkinson's disease [4–12], although etiological causes of each
disease are different.
Hepatic mitochondrial abnormalities are observed in both al-
coholic fatty liver disease (AFLD) [4–6], nonalcoholic fatty liver
disease (NAFLD) [7–9] and acute liver injury. As a result, it is
conceivable to observe decreased ATP levels and increased fat
accumulation (micro-vesicular and macro-vesicular steatosis) in
the liver under these conditions. Continued mitochondrial dys-
function with increased oxidative stress also sensitizes the hepa-
tocytes to subsequent necrosis and/or apoptosis of hepatocytes,
which likely lead to activation of resident liver macrophage (i.e.,
Kupffer cells) and recruitment of inﬁltrating immune cells into the
liver with elevated levels of hepatic inﬂammation (steatohepatitis)
and pro-inﬂammatory cytokines/chemokines [13–15]. Conse-
quently, hepatic stellate cells can be activated and transformed
into myoﬁbroblast-like cells, producing pro-ﬁbrotic cytokines such
as transforming growth factor-beta and platelet derived growth
factor, leading to hepatic ﬁbrosis/cirrhosis and cancer. These se-
quential events can be observed in both AFLD [13–15] and NAFLD
[16,17]. In addition, acute or sub-chronic exposure to various he-
patotoxic compounds, including clinically-used drugs, such as
acetaminophen (APAP) [18–20], a major ingredient of Tylenols, an
anti-breast cancer agent tamoxifen [21], an anti-retroviral drug
zidovudine (AZT) [22] and antidepressants [23], can cause mi-
tochondrial dysfunction, contributing to liver injury with or
without fat accumulation, depending on the injurious agent, as
extensively reviewed [24–26]. These hepatotoxic agents and pa-
thological conditions are known to elevate the levels of reactive
oxygen and nitrogen species (ROS/RNS) and nitroxidative stress
through the suppression of the mitochondrial electron transport
chain (ETC) and induction/activation of NADPH oxidase, cyto-
chrome P450 isozymes including ethanol-inducible P450-2E1
(CYP2E1) and CYP4A, xanthine oxidase, and inducible nitric oxide
synthase (iNOS). Although increased nitroxidative stress can oxi-
datively damage mitochondrial DNA and lipids, the majority of
insults can also take place at the protein levels through different
forms of post-translational modiﬁcation (PTM) [26,27]. Because of
the newly-emerging information on redox-related protein mod-
iﬁcations, we brieﬂy describe ﬁve major forms of PTM and func-
tional consequences of some modiﬁed mitochondrial proteins inthe experimental models of the AFLD, NAFLD and acute liver injury
(Fig. 1). In addition, we highlight potential roles of CYP2E1 in
promoting various PTMs.Post-translational modiﬁcations of mitochondrial proteins
Oxidation of mitochondrial proteins
Under normal conditions, transiently elevated ROS is known to
be involved in cellular signaling pathways [28,29] and mitochon-
drial functions are correctly maintained through proper redox
balance. However, chronic and/or binge alcohol, high fat diets,
tobacco smoking, or certain hepatotoxic drugs can directly damage
the mitochondrial ETC, producing greater amounts of ROS leaked
from the ETS [24–27]. Without proper counter-balance by various
cellular anti-oxidants, the persistent imbalance in cellular redox
states result in decreased levels of mitochondrial antioxidants in-
cluding mitochondrial glutathione (mtGSH), which serves as a
critical determinant between toxic damage and cellular protection
[30]. When the cellular defense system is overwhelmed, greater
amounts of ROS and RNS remain elevated, ultimately leading to
increased nitroxidative stress.
It is well-established that many amino acids such as cysteine
(Cys), methionine (Met), histidine (His), proline (Pro), lysine (Lys),
tyrosine (Tyr), phenylalanine (Phe), threonine (Thr) and trypto-
phan (Trp) in most proteins can also be redox regulated. As re-
cently reviewed [26,27], Cys residue(s) can be oxidatively modiﬁed
in many forms [sulfenic acid, disulﬁde, sulﬁnic/sulfonic acids, NO-
or peroxynitrite-dependent S-nitrosylation, NO-independent ADP-
ribosylation, mixed disulﬁde formation between Cys residues and
glutathione (glutathionylation), cysteine (cystathionylation), suc-
cinic acid, myristic acid [31] or palmitic acid (Cys-palmitoylation)
[32] prior to membrane attachment or cellular trafﬁcking].
Since the sensitive methods to detect redox-regulated Cys re-
sidues in cellular proteins were extensively described in our pre-
vious reviews [26,33], we will only highlight the functional con-
sequences of oxidative modiﬁcation of Cys residues in some pro-
teins. If one of these amino acids serves as the active site or is
located near the active site of certain enzymes, it is highly likely
that oxidative modiﬁcations of these amino acids can result in
their inactivation, as shown by the oxidation and/or S-nitrosyla-
tion of Cys residues including the active site Cys in the mi-
tochondrial aldehyde dehydrogenase (ALDH2) [34] and 3-keto-
acyl CoA-thiolase (thiolase) [34] in binge alcohol-exposed rodents.
In fact, mass-spectral analysis revealed that more than 87 mi-
tochondrial and 60 cytosolic proteins were oxidatively-modiﬁed in
alcohol-exposed rodents [34,35]. The rates of protein oxidation in
CYP2E1-containing E47-HepG2 hepatoma cells [36] exhibited a
dose- and time- dependent pattern in response to alcohol as well
as the presence of CYP2E1 [37]. Similar numbers of oxidatively-
modiﬁed mitochondrial proteins were also identiﬁed by mass-
spectral analysis in mice with I/R injury [38] and rats exposed to
3,4-methylenedioxymethamphetamine (MDMA) [39]. The number
of oxidatively-modiﬁed mitochondrial proteins we characterized
may represent a small fraction of the estimated number of 1100–
1400 total mitochondrial proteins [40,41]. However, we believe
that the actual number of oxidized proteins could be signiﬁcantly
higher than the proteins originally reported [34,38,39], because of
the technical limitations in the identiﬁcation and puriﬁcation of
oxidized proteins and detection methods, especially for those
proteins expressed in low abundance, as previously discussed
[26,33].
In the case of oxidative inactivation of mitochondrial ALDH2
through active site Cys modiﬁcation [42], immunoblot analysis of
the immunoafﬁnity puriﬁed ALDH2 proteins by using the speciﬁc
Fig. 1. Five major types of PTM contributing to mitochondrial dysfunction and
tissue injury in AFLD, NAFLD and acute liver damage. Alcohol, smoking, high fat
diet, hepatotoxic compounds and aberrant genetic mutations can lead to increased
production of ROS and RNS either individually or synergistically, leading to ele-
vated nitroxidative stress. Under increased nitroxidative stress, many cellular
(mitochondrial) proteins can be modiﬁed by different forms of PTM and in-
activated, leading to mitochondrial dysfunction. Under increased mitochondrial
dysfunction, greater amounts of ROS/RNS are produced while energy supply and
normal metabolism can be suppressed. Accumulation of fat resulting from dis-
rupted fat oxidation can trigger insulin resistance and lipotoxicity while protein
adducts can stimulate immune responses. Sustained mitochondrial dysfunction
would lead to the development of vicious cycles of PTMs and energy depletion and
lipotoxicity, ultimately promoting tissue injury (necrosis/apoptosis). Many small
molecule antioxidants contained in fruits and vegetables as well as exercise and
calorie restrictions can be used to prevent or reduce the nitroxidative stress. Uni-
directional and bi-directional arrows indicate exclusive and mutual inﬂuences (in
vicious cycles), respectively.
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detection using the anti-ALDH2 antibody revealed that similar
levels of ALDH2 (54 kDa) were observed in all 3 mitochondrial
samples [i.e., mitochondria from control rats, mitochondria
from alcohol-exposed rats, and dithiothreitol (DTT)-treatedMultiple PTMs :
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Fig. 2. Multiple PTM of ALDH2 protein, contributing to its inactivation. Different types of
although phosphorylation of ALDH2 by the PKCε isoformwas shown to stimulate the ALD
isozymes, all of which share the 100%-conserved active site Cys residue, likely contri
peroxides (MDA and 4-HNE) following exposure to ethanol, high fat and other toxic com
acute and sub-chronic cases. Long-term chronic suppression of ALDH2 and other isozy
represents the inactivation of ALDH2 and other isozymes.mitochondria from alcohol-exposed rats]. However, one speciﬁc
immunoreactive band with the anti-S-NO-Cys antibody was de-
tected only in mitochondria from alcohol-exposed rats. Further-
more, the signiﬁcantly decreased ALDH2 activity in ethanol-
exposed rats was fully restored by DDT treatment [34]. Similar
results of S-nitrosylation and inactivation of ALDH2 were also ob-
served in rat hepatoma H4IIE-C3 cells exposed to NO donors such
as S-nitrosoglutathione (GSNO), S-nitroso-N-acetylpenicillamine,
and 3-morpholino-sydnonimine, respectively [43]. These results
indicate that ALDH2 and other ALDH isozymes, which contain the
highly conserved active site Cys residue, can be reversibly modu-
lated by S-nitrosylation under increased nitroxidative stress, as
reviewed [42]. Other PTMs of Cys and other amino acid residues in
ALDH2 protein are summarized (Fig. 2). Oxidative modiﬁcation
and suppression of ALDH2 in alcohol-exposed rodents were con-
sistently observed by other groups [44,45]. In fact, these phe-
nomena could explain the decreased levels of ALDH2 activity in
alcoholic individuals, as discussed [34,42]. Oxidative modiﬁcation
and inactivation of ALDH2 were also observed after exposure to
MDMA [39] or I/R injury [38], resulting in the accumulation of
lipid peroxidation products, which are metabolized by ALDH2 [46].
Similar modiﬁcations and inactivation of active site Cys residues in
thiolase and possibly other enzymes in the β-oxidation pathway of
fatty acids are likely to lead to fat accumulation observed in alcohol-
exposed rodents [34], in MDMA-exposed rats [39] as well as in
mouse liver following I/R injury [38]. Furthermore, oxidative mod-
iﬁcation of the active site Cys residue of peroxiredoxin 1 (Prx1)
and inactivation was observed in alcohol-exposed mice [47]. Since
Prx1 was determined to be localized on the cytosolic side of the
endoplasmic reticulum (ER) and interacts with CYP2E1 [47], it is
likely that this oxidative inactivation of Prx1 contributes to in-
creased ROS production and fatty liver following alcohol exposure.
Based on the conserved redox-sensitive Cys residues among
the multiple isoforms [47–49], many Prx enzymes could be also
oxidatively-modiﬁed and inactivated, contributing to elevated
levels of oxidative stress. Furthermore, the activities of NADþ- or
NADPþ-dependent isocitrate dehydrogenases (ICDH) are known to
be oxidatively-modiﬁed and inactivated in experimental models
exposed to hydrogen peroxide, menadione, nitric oxide, or alcohol
[50–53]. Oxidative inactivation of ICDH enzymes would increase
oxidative stress since they are important in the regulation of mi-
tochondrial redox balance and cellular defense through providing
NADPH for the regeneration of reduced GSH [50]. Mass-spectral
analysis conﬁrmed that Cys305 and Cys387 of NADPþ-ICDH were
S-nitrosylated, resulting in its inactivation in alcohol-exposed ani-
mals [53]. By the same logic, it is expected that many other en-
zymes that contain active site Cys residue would likely undergo
similar types of redox-related modiﬁcations and become in-
activated, as reviewed [26,33]. For instance, it was reported that aER stress,
mito-dysfunction &
cell/tissue injury
Fibrosis/cirrhosis,,
DNA damage/mutation
& carcinogenesis
          Elevated
AcAH,
MDA &
HNE
acute
chronic
PTM on ALDH2 are illustrated. Most PTMs led to the suppression of ALDH2 activity,
H2 activity, as recently reviewed [42]. The suppressed activities of ALDH2 and other
bute to increased levels of toxic and carcinogenic acetaldehyde (AcAH) and lipid
pounds. ER stress, mitochondrial dysfunction and tissue injury can be observed in
mes can also contribute to ﬁbrosis, cirrhosis and carcinogenesis. The negative sign
B.-J. Song et al. / Redox Biology 3 (2014) 109–123112DNA repair enzyme O6-methylguanine-DNA-methyltransferase
which contains redox-sensitive Cys in its active site can be in-
activated through S-nitrosylation [54], resulting in increased levels
of oxidative DNA modiﬁcations, which can contribute to
carcinogenesis.
It is also possible that redox regulation can indirectly affect the
patterns of gene expression by modulating the conserved Cys re-
sidues in proteins involved in the cell signaling pathways like
many protein phosphatases (see the Section “Phosphorylation of
mitochondrial proteins”) or directly affecting many redox-sensi-
tive transcription factors such as nuclear factor-kappa B (NF-κB),
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and hypoxia-in-
ducible factor-1 (HIF-1), as recently reviewed [55]. The modulation
of transcription factors can either be harmful or beneﬁcial. For
instance, NF-κB, a critical transcription factor in inﬂammation and
innate immune regulation, can be activated by alcohol [56] and
other toxic agents such as lipopolysaccharide (LPS) [57]. NF-κB can
be activated through proteasomal degradation of the inhibitor
protein (I-κB) of the NF-κB after its phosphorylation by I-κB kinase.
Consequently, NF-κB activation leads to the transcriptional initia-
tion of many pro-inﬂammatory cytokines, chemokines and pro-
oxidant proteins such as TNF-α, IL-12, monocyte chemotactic
protein-1, macrophage inﬂammatory protein-2, cyclooxygenase-2
and iNOS [55–57]. Chronic or acute alcohol exposure and other
hepatotoxic agents can also activate HIF-1α in mice and rats
[57,58–61]. However, activation of HIF-1α, which is co-localized
with CYP2E1 in centrilobular areas, seems to contribute to
CYP2E1-dependent oxidative stress and liver toxicity, as recently
suggested in chronic and acute alcohol exposure [59–61]. In con-
trast, a cell-protective transcription factor Nrf2 can be activated
under increased oxidative stress in AFLD and NAFLD [62–65]. In-
creased oxidative stress activates Nrf2 through oxidative mod-
iﬁcations of redox-sensitive Cys residues of the regulatory binding
protein Kelch-like ECH-associated protein 1 (Keap1), leading to
ubiquitin-dependent degradation of Keap1, promoting Nrf2
translocation into the nucleus for transcriptional activation of its
downstream targets, as reviewed [66]. Activation of Nrf2 with its
down-stream target proteins, including glutamate cysteine ligase,
heme oxygenase-1, quinone reductase, and thioredoxin reductase,
provides anti-oxidant defense against increased oxidative stress
caused by alcohol exposure [62].
As described thus far, oxidative modiﬁcations of Cys residues in
many cellular proteins are associated with inactivation or sup-
pression of the activity of modiﬁed target proteins. However, re-
dox modiﬁcation of Cys, especially the mixed disulﬁde formation,
such as S-glutathionylation, can also be considered as a protective
mechanism in some cases. For instance, reversible oxidation of Cys
residues of mitochondrial NADH-dependent ubiquinone oxidor-
eductase (complex I), ALDH2, and Prx3 seem to be protective,
despite temporary inactivation, against further tissue damage
from irreversible hyper-oxidation of Cys to Cys-sulﬁnic acid
(Cys-SO2) and Cys-sulfonic acid (Cys-SO3) followed by proteolytic
degradation [67,68], as in the case of I/R injury [69–72]. It is
known that Cys-glutathionylation of mixed disulﬁde groups can
create a functional cycle consisting of the forward reaction (glu-
tathione S-transferase P) and the reverse reaction (glutaredoxin
system) [67,73,74]. Furthermore, some Cys residues can be mod-
iﬁed through adduct formation with carbonyl compounds, in-
cluding lipid peroxide 4-hydroxy-2-nonenal (4-HNE) and reactive
metabolites of APAP. However, Cys residues in the adducts with
reactive metabolites or lipid peroxides cannot be restored even in
the presence of a strong reducing agent DTT and thus are con-
sidered irreversible, as discussed [26,33]. The functional implica-
tions of some examples of these adducts are described later (see
“Section Electrophilic adduct formation of mitochondrial
proteins”).Nitration of many mitochondrial proteins
It is well-established that the physiological levels of NO pro-
duced by endothelial NOS (eNOS) and neuronal NOS (nNOS) are
relatively small and can act as a signaling molecule within the cell
or interact with surrounding cells [27,75,76]. However, many toxic
agents such as alcohol, APAP and LPS can induce iNOS, which
produces greater amounts of NO, likely leading to nitrosative/ni-
trative stress [27,75–77]. In this case, NO can interact with ROS to
produce a potently toxic peroxynitrite, which can nitrate Tyr re-
sidues to generate 3-nitroTyr (3-NT) or S-nitrosylate Cys residues
of many proteins [77]. These two PTMs can lead to alterations of
both protein structure and function, contributing to increased cell
and tissue injury.
Protein nitration may occur in various cell compartments. Al-
though the concentration of mtGSH is similar to that of cytosolic
GSH (5–10 mM), it represents a small fraction of the total cellular
GSH [30]. Because mitochondria are a major source of ROS/RNS as
previously mentioned, they can be very vulnerable to nitroxidative
damage [27]. Indeed, mitochondrial DNA is extremely sensitive to
oxidative/nitrative damage due to (A) its location closer to the
inner mitochondrial membrane; (B) the relatively low amount of
histone, anti-oxidant enzymes, and mtGSH, and (C) the low levels
of polyamines and DNA repair enzymes [78,79]. In support of the
view of mitochondrial sensitivity to nitration, it has been reported
that the turn-over rates of rat liver mitochondria proteins were
markedly decreased from few days to hours as a result of pro-
teolytic degradation following exposure to nitrating conditions
[80,81]. Interestingly, mitochondrial DNA encodes 13 polypeptides
all of which are members of the 4 mitochondrial ETC proteins,
namely Complexes I, III, IV, and V [82,83]. Taken together, mi-
tochondrial DNA mutation and/or deletion may lead to abnormal
expression or deletion of some of the ETC components, con-
tributing to mitochondrial respiratory dysfunction and more
leakage of ROS/RNS. Consequently, mitochondrial damage or dys-
function due to oxidative/nitrative protein modiﬁcations can be
expected in various pathological conditions or following exposure
to some toxic agents such as alcohol, high fat, MDMA, and APAP
[18–24,84,85]. Nitration of mitochondrial proteins and their
functional roles in fatty liver disease and/or acute liver injury have
been extensively reviewed recently [27]. For instance, NO-depen-
dent inhibition of the mitochondrial respiration was monitored in
both AFLD and NAFLD [86–90].
Since protein nitration is one of the emerging research topics in
acute tissue injury, we speciﬁcally focused on this PTM in pro-
moting mitochondrial dysfunction and acute hepatotoxicty. We
used APAP as a well-established model agent for acute drug-in-
duced liver injury (DILI) to study the functional role of nitrated
mitochondrial proteins and the mechanisms of mitochondrial
dysfunction and hepatotoxicity. APAP was ﬁrst shown to induce
and promote mitochondrial protein nitration and that peroxyni-
trite can cause mitochondrial DNA damage by Cover et al. [18].
Hepatic necrosis highly correlated with the areas of nitrated pro-
teins [91]. Direct evidence for a critical role of peroxynitrite in
APAP-mediating hepatic injury has been provided with the semi-
nal work by Knight et al. [92]. This study showed that the pro-
tective effects of GSH were mainly due to the restoration of cellular
GSH levels for efﬁcient scavenging of peroxynitrite, thus providing
direct evidence of the central role of peroxynitrite in APAP-in-
duced liver injury. CYP2E1, one of the main enzymes involved in
APAP metabolism, seems to play a critical role in APAP-induced
protein nitration and liver injury [93]. Based on these results, we
hypothesized that CYP2E1-dependent nitration of many mi-
tochondrial proteins is important in promoting mitochondrial
dysfunction and liver injury. In fact, after immunoafﬁnity pur-
iﬁcation followed by mass-spectral analysis, we demonstrated that
B.-J. Song et al. / Redox Biology 3 (2014) 109–123 113more than 70 mitochondrial proteins and 30 cytosolic proteins
were nitrated in APAP-exposed mice [94]. These results are in line
with another recent report [95]. The identiﬁed nitrated proteins
are involved in cellular energy production, fat metabolism, inter-
mediary metabolism, urea cycle, chaperone activity, and anti-oxi-
dant defense. To further determine the functional roles of protein
nitration, we mainly focused on the ﬁve selected mitochondrial
enzymes, namely SOD2, Gpx, ATP synthase, ALDH2 and thiolase.
We speciﬁcally studied the presence of nitration and activity
change in each of these ﬁve enzymes at 2 h after exposure to a
toxic dose of APAP in the presence or absence of the co-treatment
with an anti-oxidant N-acetyl-cysteine (NAC) [94]. Treatment with
NAC completely protected the liver from the APAP-induced ne-
crotic injury measured by increased serum transaminase activities
and liver histology. Furthermore, NAC ameliorated the inactivation
of the ﬁve critical enzymes via preventing Tyr nitration, as evi-
denced by immunoprecipitation with a speciﬁc antibody to each
protein followed by immunoblot with anti-3-NT antibody. Thus,
protein nitration serves as one of the critical causal factors in
APAP-induced acute liver damage usually observed at later time
points. Indeed, the suppressed activities of anti-oxidant enzymes
such as SOD2 and Gpx would certainly interfere with the cellular
anti-oxidant abilities. Suppressed ATP synthase activity would lead
to decreased ATP production, interfering with vital cell functions
and ultimately causing necrosis. Furthermore, inactivation of
thiolase likely leads to the inhibition of the β-oxidation of fatty
acids with increased hepatic fat accumulation or inefﬁcient supply
of an alternative energy (e.g., ketone bodies produced from fat
degradation). Furthermore, suppressed ALDH2 would lead to the
accumulation of toxic, reactive aldehydes and lipid peroxidation,
as previously mentioned in the oxidation section [42]. Based on
our results, we expect similar results of mitochondrial dysfunction
and tissue injury with other conditions such as I/R injury [38] and
LPS treatment [96], which caused extensive protein nitration. It is
important to mention that the inactivation of many nitrated pro-
teins can result from the nitration of Tyr residue in the active site,
leading to interference of the protein’s catalytic activity. However,
it is still possible that nitration of other Tyr residues may cause a
conformational change in the target protein and thus block the
accessibility of ATP or substrates for example, as previously dis-
cussed [27]. However, it would be prudent to double-check the
function of each nitrated protein, since nitration can also increase
the activity of some proteins such as glutathions S-transferase
(GST), heat shock protein 90 (HSP90), and protein phosphatase
type 2 [PP2], or exert no effects at all as reported with transferrin
[27].
Although most reported results mainly focused on Tyr nitra-
tion, nitration of Trp residues in proteins was also reported [97].
However, there have been fewer reports about Trp nitration and
functional consequence than those of Tyr nitration, since Trp is
much less abundant than Tyr and that Trp is usually buried inside
the protein core with less surface exposure for nitration. None-
theless, excellent reports discussed the occurrence of Trp nitration
that may cause functional alterations in detail [97–99]. The effects
of peroxynitrite on nitration of Tyr or Trp and S-nitrosylation of
Cys likely depend on cellular status of antioxidants, various mi-
croenvironments including surface exposure, peptide loop struc-
ture, local charge groups, and the presence of competing amino
acids nearby (e.g., Cys near the potentially-nitrated Trp or Tyr), as
suggested [98].
Phosphorylation of mitochondrial proteins
Many cellular proteins can be regulated by reversible cycles of
phosphorylation and dephosphorylation by protein kinases and
phosphatases, respectively. It is well-established that manyexogenous agents such as alcohol, smoking, high fat, and APAP can
modulate many different classes of protein kinases including
cAMP-dependent protein kinases (PKA), PI3K/AKT/mTOR (PKB),
protein kinase C isoforms (PKC), calcium-calmodulin-dependent
protein kinases, stress activated mitogen-activated protein kinases
(MAPKs) including c-Jun N-terminal protein kinase (JNK) and p38
kinase (p38K), and receptor-mediated tyrosine kinases. These ki-
nases can work together synergistically or antagonize each other’s
activities. In fact, crosstalk between different classes of protein
kinases becomes complicated, contributing to different outcomes,
depending on their inducibility, tissue distribution, subcellular
localization or translocation to another compartment, cellular
environment, treatment agent, and activity status of phospho-
protein phosphatase, as recently reviewed [100–105]. For instance,
concurrent activation of PKC-delta isoform along with stress acti-
vated protein kinases generally enhances cell death [106–108],
although some exceptions exist. In contrast, activation of PI3K/Akt
and extracellular signal regulated protein kinase (ERK) is generally
known to support cell survival and proliferation. However, we
brieﬂy describe the redox-mediated regulation of stress activated
MAPKs and AMP-activated protein kinase (AMPK) in this review,
based on their involvement in mitochondrial homeostasis, inter-
mediary metabolism for steatosis and liver injury.
Under increased nitroxidative stress, stress-activated MAPKs
can be stimulated partly through inhibition of phosphoprotein
phosphatases. For instance, the highly-conserved active site Cys
residue of phosphoprotein phosphatases including MAPK phos-
phatases [103–105] can be oxidatively-modiﬁed and inactivated by
the mechanisms described earlier (“Section of Oxidation of mi-
tochondrial proteins”). This redox-related activation of MAPKs is
similar to that of Akt activation through oxidative inactivation of
the essential Cys residue of its binding partner lipid phosphatase
and tensin homolog (PTEN) [109]. The inactivation of MAPK-
phosphatases leads to activation of various stress-activated JNK
and p38K [104,105]. In fact, acute exposure to many hepatotoxic
agents including alcohol [110,111], APAP [112–116], arachidonic
acid [117], 4-HNE and carbon tetrachloride [118], palmitic acid
[119], and troglitazone [120] signiﬁcantly activated JNK (p-JNK)
and/or p38K (p-p38K), contributing to toxicity in a variety of cells.
Pretreatment with a speciﬁc inhibitor of CYP2E1 blocked meta-
bolic activation of some hepatotoxic agents, which are CYP2E1
substrates [110–118], and prevented JNK activation. Taken to-
gether, CYP2E1 is critically involved in JNK activation and cell
death caused by those hepatotoxic CYP2E1 substrates. In addition,
activation of JNK was positively related to high fat diet-induced
insulin resistance and metabolic syndrome [119,121–123]. A recent
study also showed that sustained JNK activation led to phos-
phorylation at Ser-46 of sirtuin 1, NADþ-dependent deacetylase in
cytosol (described later), followed by ubiquitin-dependent de-
gradation, contributing to fat accumulation in obese mice [124].
Furthermore, persistent activation of JNK and/or p38K is positively
associated with various liver diseases such as steatohepatitis and I/
R injury [122–125], suggesting the clinical importance of JNK and
p38K in human disease states, as reviewed [126]. Experiments
with gene deletion technology and anti-sense oligonucleotides
were conducted to determine the role of JNK1 versus JNK2 in
hepatotoxicity. For instance, both JNK1 and JNK2 seem to be im-
portant in alcohol-induced fatty liver injury [111], while JNK1
seems critical in hepatotoxicity caused by co-treatment of pyrazole
and TNFα [127]. In contrast, JNK2 plays a dominant role in APAP-
induced acute liver injury since JNK2-null mice are resistant to
acute hepatotoxicity [113], suggesting that this area needs further
clariﬁcation.
Several reports on the redox-related activation of the JNK and/
or p38K or their upstream kinases such as mitogen activated
protein kinase kinase (M2K) and mitogen activated protein kinase
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identity of the mitochondrial and cytosolic proteins, that are
phosphorylated by active p-JNK and/or p-p38K, need to be in-
vestigated. Our results showed that pro-apoptotic Bax in the cy-
tosol can be phosphorylated (activated) by p-JNK and/or p-p38K,
resulting in its conformational change with exposure of the
C-terminal membrane domain. These events were followed by
translocation of the activated Bax to mitochondria, leading to
changes in mitochondrial permeability transition (MPT) and
apoptosis of cultured hepatoma cells [129]. The importance of
phosphorylation was further conﬁrmed using site-directed muta-
genesis of potential amino acids for phosphorylation followed by
functional analysis. Our results revealed that Thr167 of Bax was
phosphorylated before it was translocated to mitochondria to
stimulate mitochondria-dependent apoptosis [129]. In addition,
activated p-JNK is known to translocate to mitochondria to initiate
MPT change and damage following exposure to hepatotoxic agents
including APAP [115,116,130,131]. Since JNK does not contain the
canonical mitochondrial leader sequence [132], it would be in-
teresting to identify the mechanism(s) by which activated p-JNK is
transported into mitochondria and then phosphorylates mi-
tochondrial matrix proteins such as ALDH2 in CCl4-exposed rats
[133]. One of the potential mechanisms of JNK translocation to
mitochondria could be through its interaction with a scaffold
protein Sab [116,134] or Bcl-XL [130] on the mitochondrial outer
membrane before it gets transported into mitochondria. When the
active p-JNK is translocated to mitochondria, it can phosphorylate
many mitochondrial proteins such as ATP synthase β subunit, α-
KGDH, PDH E1α and β subunits, which were phosphorylated by the
recombinant JNK, as shown in an in vitro study using bioenerge-
tically competent mitochondria [135]. However, the identities and
physiological roles of numerous mitochondrial proteins phos-
phorylated by p-JNK (e.g., JNK-speciﬁc phosphoproteomes) need
to be determined in animal models and human disease states in
the future.
Regulatory mechanism of AMP-dependent protein kinase
(AMPK) by alcohol and other non-alcoholic substances, including
high fat diet has become an important research topic, since AMPK
serves as a key sensor and/regulator of metabolic syndrome and
many cellular processes [136]. In fact, the redox sensitive AMPK
can be paradoxically regulated by activation or suppression. For
instance, AMPK can be activated by hydrogen peroxide and mi-
tochondria-derived ROS since its activation can be prevented by
pretreatment with antioxidants such as NAC or GSH-ethyl ester
[101]. AMPK activation by hydrogen peroxide was tightly asso-
ciated with the elevated levels of AMP with concurrent depletion
of ATP. Recent results showed that AMPK can be also activated in
an AMP-independent manner. Regardless of AMP dependency,
AMPK activation under oxidative stress or by chemical activators
such as metformin and AICAR can lead to increased cell survival
signal by promoting autophagy to remove damaged mitochondria
and to stimulate mitochondrial energetics [101]. In contrast, AMPK
can be suppressed by alcohol [137] or other agents such as high fat
diet [138] and APAP [139]. Inactivation of AMPK is known to be
associated with AFLD and NAFLD or acute liver injury, as reviewed
[13].
Acetylation of mitochondrial proteins
Reversible protein acetylation and deacetylation, catalyzed by
acetyltransferases and deacetylases, respectively, represent another
form of PTMs, although functional roles of many acetylated proteins
are still unclear and need further investigations. In fact, acetylation on
N-ε-Lys residues in proteins becomes an important research area
through epigenetic regulation of many genes involved in normal
cellular growth and physiology by acetylated histones and otherchromatin associated proteins [140]. A large scale proteomics study
revealed that approximately 20% of mitochondrial proteins and 44% of
NADþ-dependent mitochondrial dehydrogenases are acetylated un-
der physiological conditions [141]. The number of acetylated proteins
can be signiﬁcantly increased in experimental models of pathological
conditions or following exposure to hepatotoxic agents, possibly re-
sulting from redox-mediated suppression of deacetylases, as shown in
alcohol-exposed [142–145] or high-fat exposed rodents [146–148].
For instance, chronic and binge alcohol exposure suppressed the ac-
tivities or decreased levels of various isoforms of sirtuin, Zn and
NADþ-dependent deacetylases, involved in cellular aging, lipid me-
tabolism, and anti-oxidant defense. Because of NADþ-dependence,
the activities of sirtuins can be suppressed by the redox change (e.g., a
decreased NADþ/NADH ratio) following alcohol metabolism via al-
cohol dehydrogenase (ADH) and low Km ALDH2, both of which use
NADþ as a cofactor for their activities. Earlier reports also showed
that chronic alcohol exposure suppressed the activities and protein
amounts of sirtuin 1, 3 and 5 isoforms [142–145,149,150], in a
CYP2E1-independent manner [144]. In addition, the activities of sir-
tuin isoforms can be allosterically suppressed through thiol-speciﬁc
modiﬁcation of Cys280 in the Zn binding site with 4-HNE adduct
formation, as demonstrated [151]. Consequently, the levels of acety-
lated proteins were signiﬁcantly elevated in alcohol-exposed rodents.
Some of the acetylated proteins, that are deacetylated by sirtuin iso-
forms, are several transcription factors involved in the regulation of
lipid metabolism and cell apoptosis such as sterol regulated element
binding protein (SREBP), peroxisomal proliferator activated receptor
gamma coactivator-1 (PGC-1), forkhead box protein O1 (FoxO1), NF-
κB and p53 [142–144,149]. Acetylation of these transcription factors is
a well-established cause for fat accumulation and altered cell pro-
liferation in the liver. For instance, alcohol-related suppression of
sirtuin 1 increased the levels of acetylated SREBP-1 and PGC-1α with
functional activation and suppression, respectively, resulting in alco-
holic fatty liver [142]. By using immunoprecipitation with anti-Ac-Lys
antibody followed by mass spectral analysis, 91 acetylated mi-
tochondrial proteins were recently identiﬁed in alcohol exposed mice
[152]. Some of the acetylated mitochondrial proteins are ALDH2, ATP
synthase, Gpx, and thiolase, suggesting that these acetylated mi-
tochondrial proteins likely contribute to their functional alterations
and fat accumulation [152]. Another report further indicated that al-
cohol treatment elevated the number of acetylated proteins as well as
propionylated protein in mitochondria and nuclear fractions with
little changes in cytosolic and microsomal fractions through sup-
pression of sirtuin activities [153]. However, in this study, alcohol-
exposure did not seem to change the protein levels of sirtuin 3, 4, and
5. The reasons for dissimilar results on sirtuin levels, observed in
different laboratories, are unknown, but could be due to distinct
ethanol dose, time course, environment, or animal strains, and war-
rants further investigation.
In addition, high fat feeding can suppress the activities of mi-
tochondrial sirtuin 3 and other isoforms, thus increasing the
number of acetylated proteins. However, the mechanism(s) by
which high fat decreased levels of sirtuin isoforms is poorly un-
derstood. The levels of hyper-acetylated proteins are markedly
increased in mice deﬁcient of mitochondrial sirtuin 3
[147,154,155]. For instance, acetylation of long-chain fatty acyl-
CoA dehydrogenase, one of the four enzymes involved in the mi-
tochondrial fat oxidation pathway, causes its inactivation, leading
to fat accumulation [154,155]. In contrast, activation of sirtuins by
small molecule polyphenols including resveratrol [156] and green
tea extracts [157] can reduce the number of acetylated proteins,
including PGC-1α, which contributes to increased fat oxidation and
insulin sensitivity with improved outcome against metabolic
syndrome. Therefore, sirtuin 3 and its isoforms, involved in fat
metabolism and aging process, become important therapeutic
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in the liver and other tissues.
As mentioned earlier, key mitochondrial proteins in regulating
the fatty acid metabolism are acetylated and that the number of
acetylated proteins can be signiﬁcantly increased through sup-
pression of the mitochondrial deacetylase sirtuin 3 and other sir-
tuin isoforms by alcohol [142–145,149,150–153], high fat [148],
and other conditions [154,155]. Compared to numerous reports on
the regulation of deacetylase proteins including mitochondrial
sirtuin 3, the expression and properties of the mitochondrial
acetyltransferase enzyme(s) have been less characterized although
acetylation sites in many mitochondrial proteins have been re-
cently reported [158]. In addition, other studies indicated that
protein acetylation can take place nonenzymatically in the pre-
sence of low levels of acetyl-CoA [159] or acetyl-phosphate and
acetyl-adenylate [160]. These reports indicate that the character-
istics of acetyltransferase(s) are poorly understood and need fur-
ther studies, although the GCN5 family seems to be the prototype
of (histone) acetyltransferases [161].
Electrophilic adduct formation of mitochondrial proteins
It is well-established that excessive alcohol intake and many
potentially toxic compounds can suppress low Km mitochondrial
ALDH2 activity in rodents and humans through various PTMs of
the active site Cys residue and other redox-sensitive amino acids,
as reviewed [26,27,42], resulting in the accumulation of toxic
acetaldehyde and other lipid aldehydes. Consequently, cellular
macromolecules including mitochondrial proteins [162,163] and
DNA [164] are subjected to modiﬁcation by these toxic aldehydes,
leading to mitochondrial dysfunction and oral and gastrointestinal
tract cancers [165]. Chronic alcohol drinking and/or smoking or
high fat can also cause mitochondrial damage with increased ni-
troxidative stress and lipid peroxidation products such as 4-HNE,
4-oxonon-2-enal [4-ONE], malondialdehyde (MDA), and acrolein
(ACR) [166–168]. In addition, many potentially toxic drugs can
produce reactive metabolites, which can induce mitochondrial
dysfunction and acute liver injury [18–21,24]. For instance, APAP
metabolism produces N-acetyl-p-benzoquinone imine (NAPQI)
while the metabolism of potentially hepatotoxic troglitazone
generates reactive quinolone-like metabolites. Other drugs such as
halothane, tienilic acid, and dihydralazine can produce reactive
metabolites, which promote hepatotoxicity. The underlying me-
chanisms of these idiosyncratic toxicities by these agents could be
due to interactions between highly reactive electrophilic inter-
mediates with various mitochondrial proteins, leading to mi-
tochondrial dysfunction and tissue damage including DILI. They
can also damage membrane integrity and alter calcium home-
ostasis between endoplasmic reticulum and mitochondria, leading
to hepatotoxicity. Furthermore, these protein adducts can serve as
a neo-antigen of hapten–carrier conjugate proteins to activate
immune responses and to facilitate inﬁltration of neutrophils into
the liver to promote inﬂammation [18–21,24,166–168].
Recent results showed that highly-reactive lipid peroxides in-
cluding 4-HNE and 4-ONE, despite their extremely short half-lives,
can suppress the activities of many mitochondrial proteins likely
through adduct formation with a few amino acids such as Cys, His,
Arg, and Lys of target proteins [168]. For instance, earlier reports
showed that acetaldehyde and 4-HNE produced by alcohol intake
interact with mitochondrial proteins, including cytochrome C
oxidase (complex IV), leading to its inactivation, mitochondrial
dysfunction and liver injury [169–172]. By using mass-spectro-
metry, Petersen and colleagues recently determined the speciﬁc
amino acids that are modiﬁed by 4-HNE. They showed that the
active site Cys301 of ALDH2 [173] and Cys280 in the critical Zn
binding site of sirtuin 3 [151] were covalently modiﬁed with4-HNE, leading to their inactivation. In addition, many other pro-
teins such as protein disulﬁde isomerase [174] and Grp78 [175] in
the ER, gamma-glutamyl-cysteine synthase (GCS) [176], ERK [177],
PTEN [178], or AMPK [179] in cytosol could also be inactivated
through interaction with 4-HNE, likely leading to ER stress, GSH
depletion and alteration of the cell signaling pathways frequently
observed in alcohol-fed models and humans.
Unlike mixed disulﬁde bonds of Cys such as S-nitrosylation and
S-glutathionylation, the protein adducts with reactive carbonyls
including 4-HNE, 4-ONE, MGO and ACR cannot be reversed by the
presence of reducing agents such as DTT, GSH and ascorbate, as
recently reviewed [28]. Therefore, these protein adducts may exist
for an extended time period unless they are removed by cellular
proteolytic enzymes or phagocytic macrophages. Furthermore,
HNE-protein adducts can induce immune cell activation of hepatic
macrophage Kupffer cells and/or inﬁltration of neutrophils into the
liver, producing inﬂammatory cytokines and activation of stellate
cells, leading to advanced liver disease, as reported in alcoholic
liver injury [166–168,180]. In fact, the average levels of MDA- and
HNE-protein adducts in 50 alcoholic cirrhosis patients were sig-
niﬁcantly higher than those in a similar number of patients with
nonalcoholic cirrhosis or healthy individuals [180]. In contrast, no
differences in the levels of ACR- and MGO-protein adducts were
found among different groups. Furthermore, the average levels of
MDA and HNE-adducts were higher in 51 alcoholic patients with
advanced liver disease with ﬁbrosis/cirrhosis than 23 fatty liver
disease or 30 healthy control people, suggesting that MDA- and
HNE-protein adducts likely served as antigens or activators of
immune responses in advanced alcoholic liver disease. The etha-
nol-induced CYP2E1 was partly responsible for the production of
37 kD-acetaldehyde protein adducts [181] while 4-HNE protein
adduct could be produced in CYP2E1-independent manner, al-
though CYP2E1 seems to at least play a permissive role [182].
In case of high-fat fed rodents, the total number of the reports on
HNE-protein adducts in the livers of NAFLD seems relatively small
compared to those in AFLD, although the identities of HNE-protein
adducts were reported in extra-hepatic tissues such as heart
[183,184]. Mass spectral analysis revealed 39 unique lipoxidation
sites in 27 mitochondrial proteins. These lipid peroxide-modiﬁed
mitochondrial proteins include: pyruvate dehydrogenase, malate de-
hydrogenase, ICDH, methylmalonate-semialdehyde dehydrogenase,
long chain fatty acyl-CoA dehydrogenase, NADH-dependent ubiqui-
none oxidoreductase (complex I), succinate dehydrogenase (complex
II), ubiquinone-cytochrome bc1 oxidoreductase (complex III), cyto-
chrome c oxidase (complex IV), ATP synthase (complex V), and others
[184]. Although the activities of each HNE-modiﬁed protein were not
determined in this study, it is reasonable to assume that the func-
tional activities of some of the modiﬁed proteins could be suppressed.
We also believe similar types of lipid peroxide adducts present in the
liver of high-fat exposed rodents (and humans), due to the elevated
levels of oxidative stress and lipid peroxides including 4-HNE [185], as
comparable to the alcoholic fatty liver [170–172]. In fact, ALDH2 ac-
tivity in the heart was signiﬁcantly inhibited in high fat-exposed
diabetic mice [186]. Further characterization revealed that ALDH2was
inactivated through 4-HNE adduct formation, as evidenced by im-
munodetection of 4-HNE adduct in the immunoprecipitated ALDH2
with the anti-ALDH2 antibody [186]. The levels of cardiomyocyte
hypertrophy and dysfunction in high fat-exposed mice were inversely
correlated with the ALDH2 activity, suggesting a causal role of ALDH2
in diabetic cardiomyopathy. These results are consistent with the
cardioprotective role of ALDH2 which can be activated by small
molecule activators [42,187] or over-expression by genetic modula-
tion [188,189].
In addition to lipid peroxide-related protein adducts, recent
data suggest that sugar moiety-related protein adduct such as
advanced glycation end products (AGEs) can be produced by high
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as diabetes, cardiovascular diseases and Alzheimer's disease, as
recently reviewed [190–193]. Elevated levels of cross-linked AGEs
in many tissues can up-regulate the expression of the receptor for
AGEs (RAGE), which activates NADPH oxidase, leading to increased
oxidative stress, insulin resistance, and inﬂammation with dis-
ruption of normal cell signaling pathways. These pro-oxidative
events with accumulated proteins contribute to acute injury and/
or persistent chronic disease states in many tissues [190–193]. For
instance, chronic alcohol exposure elevated the levels of acet-
aldehyde-derived AGE (AA-AGE) and HNE-protein adducts in the
livers of rats and humans while their elevated levels disappeared
after alcohol abstinence. The immunostaining intensities of AA-
AGE and HNE-adducts positively correlated with the severity of
alcoholic liver disease [193]. Furthermore, AA-AGE but not N-
ethyllysine (NEL) caused apoptosis of rat hepatocytes, suggesting
an important role of AA-AGE in alcohol-induced hepatotoxicity
and fatty liver injury [193]. Similar results of elevated production
of AGE and its plasma levels in cirrhotic patients compared to
those in healthy individuals were previously reported [194]. High
fat feeding also elevated the levels of AGEs and RAGE in many
tissues, including kidneys, hearts and epididymal fat in an aldose
reductase-dependent manner [195]. In a mouse model of NASH
caused by high fat western diet or choline-deﬁcient diet, AGEs
induced TNFα-cleavage enzyme in an NADPH oxidase-dependent
manner and stimulated ﬁbrogenic activity via decreasing the le-
vels of sirtuin 1 and tissue inhibitor of metalloproteinase 3
(TIMP3) [196]. The signiﬁcantly lower levels of sirtuin 1 and TIMP3
were also observed in livers from NASH patients than those of
healthy individuals, suggesting a role of AGE adducts in promoting
inﬂammatory responses. Another report recently indicated that
several mitochondrial proteins in aged rats were modiﬁed with
AGEs, thus their activities inactivated. These AGE-modiﬁed pro-
teins were: complexes I and V, catalase, ALDH2, medium chain
acyl Co-A dehydrogenase, keto-acyl CoA dehydrogenase, and oth-
ers, leading to decreased ETC, anti-oxidant defense and urea cycle
in aged animals [197].
In addition to liver injury, AA-AGE but not NEL stimulated
death of neuronal cells [198], suggesting an important role of AA-
AGE in neuronal cell death. Consistent with this report, elevated
amounts of AGE-albumin adduct, produced by activated microglial
cells, were found in alcohol-exposed rat brains and post-mortem
brains from human alcoholic individuals compared to those of
healthy normal counterparts [199]. Increased oxidative stress can
produce AGE-albumin adduct, which elevates the level of RAGE
and activates JNK- and p38K-mediated death of neuronal cells.
These results are in agreement with the increased expression of
RAGE in the brains of alcohol-exposed rats and humans [200].
Consistently, the elevated amounts of AGE-albumin, which was
conﬁrmed by mass-spectral analysis [201], were found in the
brains of Alzheimer’s disease patients than those of the healthy
individuals [202]. Inhibition of AGE-albumin production or block-
ade of RAGE by a chemical antagonist or a speciﬁc antibody to
RAGE efﬁciently prevented alcohol-induced brain damage [199],
suggesting an important role of AGE-protein adducts in promoting
neurodegeneration. Based on these recent results [199–202], it
would be of interest to study the role of AGE-protein adducts in
promoting organ damage in the peripheral tissues such as the liver
and heart.Fig. 3. Overlapping PTMs between AFLD and NAFLD. Overlapping PTMs commonly
observed in both AFLD and NAFLD are illustrated. However, acetaldehyde–protein
adduct (AA–adduct) [171,181], NEL-adduct [193], AA-AGE-adduct [193], and hy-
droxyethyl-adduct [203,204] seem uniquely observed in AFLD. These PTMs ob-
served in AFLD and NAFLD are likely to suppress the functions of the target pro-
teins, contributing to altered cell signaling, ER stress, mitochondrial dysfunction, fat
accumulation and inﬂammatory tissue injury.Translational research with mitochondrial-targeted
antioxidants
As described above, the increased nitroxidative stress in AFLD
and NAFLD or after exposure to hepatotoxic agents can stimulatemultiple PTMs, including the hydroxyethyl-adducts observed in
alcohol-exposed rats [203] and individuals [204] (Fig. 3). All these
PTMs of cellular proteins are likely to contribute to increased ER
stress and mitochondrial dysfunction, leading to energy depletion,
fat accumulation, altered metabolism, inﬂammation and necrotic/
apoptotic tissue damage (Fig. 3). Since elevated nitroxidative stress
is a critical contributing factor for acute and chronic liver diseases,
beneﬁcial effects of many anti-oxidants from natural and synthetic
origins have been tested in experimental model systems. These
anti-oxidant agents include: L-arginine, small molecule metabo-
lites (e.g., GSH-ethyl ester and NAC), natural antioxidants [e.g.,
vitamins C, E, co-enzyme Q10, alpha-lipoic acid, ﬁsh oil containing
n-3 fatty acids, betaine and S-adenosyl-methionine (SAMe)], and
herbal molecules and polyphenols (curcumin, esculetin, sulfor-
aphane, resveratrol, epigallocatechin-3-gallate, caffeic acid phe-
nethyl ester, and many others) [205–211]. Some of these anti-
oxidants, contained in many fruits and vegetables, show beneﬁcial
effects on obesity, NAFLD and liver injury [205–208] while other
antioxidants are potentially neuroprotective. Recent reports
showed that naturally occurring antioxidants such as SAMe and
betaine preserved mitochondrial function and proteome in the
animal models of AFLD [212–214] as well as NAFLD [215–217],
partly through blockade of the ROS/RNS production with restoring
the physiological levels of SAMe, S-adenosyl-homocysteine and
GSH. Nonetheless, the list of these antioxidants with therapeutic
potential is exponentially growing and will reduce the oxidative
burden in various pathophysiological conditions including fatty
liver disease.
One of the main problems with some of the natural anti-
oxidants is to guarantee good manufacturing quality control [e.g., a
constant amount of the active component(s) with acceptable le-
vels of impure materials]. Other problems can be low solubility,
poor bioavailability and little mitochondrial transport [208–211].
To overcome these problems, many compounds with better mi-
tochondrial targeting properties have been synthesized to prevent
or treat mitochondrial dysfunction in many pathological condi-
tions [211,218–225]. For instance, to accomplish better mi-
tochondrial transport, Szeto and Schiller developed a series of
small, cell-permeable, mitochondria targeted antioxidant peptides
(Szeto–Schiller or SS-tetrapeptide) that protect mitochondria from
oxidative damage [220]. These peptide antioxidants represent a
novel approach with targeted delivery of antioxidants to the inner
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tides centers on alternating aromatic residues and basic amino
acids (aromatic-cationic peptides) that can scavenge hydrogen
peroxide and peroxynitrite while they inhibit lipid peroxidation.
Their antioxidant activities can be attributed to the tyrosine or
dimethyltyrosine residue with inhibition of mitochondrial per-
meability transition and cytochrome c release, thus preventing
oxidant-induced cell death. Because these peptides can accumu-
late 41000-fold in the inner mitochondrial membrane, they
prevent oxidative cell death with EC50 in the nM range. Simi-
larly, the analogs of SOD-catalase mimetics also showed beneﬁcial
effects on many tissues including the liver and brain [221].
In contrast to the SS-peptides or peptide-mimetics, a small
molecule triphenyl phosphonium (TPPþ , a cell permeable lipo-
philic cation) has been developed to conjugate with various drugs
and antioxidants to enhance the transport of target molecules to
reduce oxidative stress and damage, as reviewed [222,223]. The
results with mitochondria-targeted ubiquinone (MitoQ) or mi-
tochondria-targeted carboxy-proxyl (Mito-CP) so far have shown
promising results in preventing mitochondrial abnormalities and
nitroxidative tissue injury in various disease models including
Friedreich Ataxia ﬁbroblasts [224], diabetic nephropathy [225],
cisplatin-induced renal toxicity [226] and cocaine-induced cardiac
dysfunction [227]. In addition, the protective effects of MitoQ and
Mito-CP were clearly demonstrated in a mouse model of hepatic I/
R injury [228]. In a dose-dependent manner, these mitochondria-
targeted compounds blocked the early and delayed nitroxidative
stress responses (e.g., HNE/carbonyl adducts, malondialdehyde,
8-OHdG, and 3-nitrotyrosine formation), mitochondrial dysfunc-
tion and histopathological signs of liver injury as well as delayed
inﬂammatory cell inﬁltration and cell death [228]. Consistently,
mitoQ was shown to be protective against micro- and macro-ve-
sicular steatosis in AFLD [229] without affecting the levels of
CYP2E1 and ALDH2 as well as ethanol-induced mitochondrial re-
spiratory abnormality. The effects of mitoQ were rather mediated
through the suppression of ROS/RNS production and their down-
stream targets such as protein nitration and HIF-1α stabilization
[229]. These promising results from different laboratories suggest
that mitochondria-targeted antioxidants are more effective against
elevated nitroxidative stress than untargeted natural antioxidants.
Because of the recent development of these antioxidant agents
and clinical testing [230,231], we expect approval of some of these
beneﬁcial agents in treating mitochondrial dysfunction-related
organ damage and hence preventing the health deterioration.Conclusion and future research opportunities
We have thus far brieﬂy described ﬁve major types of PTMs
that promote mitochondrial dysfunction, fat accumulation, in-
ﬂammation and hepatic injury in alcoholic and nonalcoholic sub-
stances (Fig. 1). Although several PTMs in many mitochondrial
proteins were identiﬁed in different disease states or under in-
creased nitroxidative stress, it is quite possible that many proteins
can be modiﬁed by multiple PTMs simultaneously. Therefore, it
seems difﬁcult to clearly demonstrate the deleterious effect of
each single PTM and which PTM plays a critical role in causing
mitochondrial dysfunction and tissue damage. In addition, it is
challenging to identify the modiﬁed amino acid(s) and their roles
in activity changes. It is also still unknown what other proteins,
especially those expressed in low amounts in a particular tissue,
are modiﬁed by different PTMs following exposure to a potentially
toxic agent. Furthermore, mitochondrial functions can be altered
by other types of PTM such as methylation, O-linked glycosylation
(Ser or Thr), N-linked glycosylation (Asn), sumoylation, and ubi-
quitin conjugation. The identities of the proteins modiﬁed by thesePTMs and their roles in mitochondrial dysfunction, fat accumula-
tion and tissue injury need to be studied in the future. Finally, the
patterns of PTM and their functional roles in other extra-hepatic
tissues such as brain, heart, pancreas, adipose tissue and intestine
need to be investigated. For instance, binge alcohol exposure
[232–239] and nonalcoholic substances including fructose [240–
242] are known to promote gut leakiness, contributing to more
severe inﬂammatory liver disease. In the case of binge alcohol-
induced gut leakiness, CYP2E1-mediated increased oxidative
stress plays an important role, since treatment with an antioxidant
NAC or a CYP2E1 inhibitor chlormethiazole signiﬁcantly prevented
gut leakiness and liver injury. In addition, Cyp2e1-null mice were
resistant to alcohol-mediated gut leakiness, which was clearly
observed in the corresponding wild-type mice [238]. It is of in-
terest whether gut leakiness caused by nonalcoholic substances
also depends on CYP2E1-mediated oxidative stress. Despite nu-
merous reports on gut leakiness caused by alcohol and fructose
[232–242], the functional roles of redox-regulated PTMs on many
intestinal proteins are still poorly understood. Therefore, char-
acterization of the modiﬁed proteins and their functional con-
sequences in intestinal epithelial tissues and other tissues are not
only good for basic mechanistic studies in understanding tissue–
tissue interactions but also provide future translational and clinical
research opportunities.Acknowledgments
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